Business
Prinses Máxima Center for Pediatric Oncology Implements Callisto™ from Volta Labs to Streamline Clinical Genomics Workflows
Volta Labs today announced that the Prinses Máxima Center for Pediatric Oncology has acquired the Callisto™ platform to streamline sample preparation across multiple genomics workflows, supporting both Illumina and Oxford Nanopore Technologies (ONT) sequencing platforms.
About this update from Oxford Nanopore Technologies Plc
[{"type":"text","content":"BOSTON, Sept. 10, 2025 /PRNewswire/ -- Volta Labs today announced that the Prinses Máxima Center for Pediatric Oncology has acquired the Callisto™ platform to streamline sample preparation across multiple genomics workflows, supporting both Illumina and Oxford Nanopore Technologies (ONT) sequencing platforms.","length":310,"tagName":"p"},{"type":"image","alt":"Volta Labs, a genomics applications company, is transforming the way biological research and analyses are performed with a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation. (PRNewsfoto/Volta Labs Inc.)","displaySize":"","headline":null,"caption":"Volta Labs, a genomics applications company, is transforming the way biological research and analyses are performed with a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation. (PRNewsfoto/Volta Labs Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/023dbe661de63404add8b58bdfdc48a3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AHxscU1_PQOYrwstr4TxAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/023dbe661de63404add8b58bdfdc48a3","width":400,"height":95}},"href":"https://mma.prnewswire.com/media/2611556/VoVolta_Labs_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Prinses Máxima Center is the largest pediatric cancer center in Europe, dedicated to integrating care and research to improve outcomes for children with cancer. By adopting Callisto, the Center will advance sample preparation across multiple genomics workflows. This implementation will increase efficiency and reproducibility while reducing hands-on time for laboratory staff.","length":381,"tagName":"p"},{"type":"text","content":""Callisto's full walk-away automation for multiple sequencing approaches will allow us to establish Illumina whole-genome sequencing as a standard of care for all pediatric patients, while at the same time supporting the adoption of Oxford Nanopore sequencing for rapid diagnosis," said Bastiaan Tops, Head of Laboratory for Childhood Cancer Pathology at Prinses Máxima Center. "By simplifying complex sequencing workflows, Callisto frees our team to focus more...